Effect of placental growth factor in models of experimental pre-eclampsia and trophoblast invasion.


Journal

Clinical and experimental pharmacology & physiology
ISSN: 1440-1681
Titre abrégé: Clin Exp Pharmacol Physiol
Pays: Australia
ID NLM: 0425076

Informations de publication

Date de publication:
01 2020
Historique:
received: 14 05 2019
accepted: 22 08 2019
pubmed: 28 8 2019
medline: 4 5 2021
entrez: 28 8 2019
Statut: ppublish

Résumé

Placental growth factor (PlGF) is decreased in early gestation of pregnant women who subsequently develop pre-eclampsia. In this study, pre-emptive treatment with PlGF to prevent pre-eclampsia was evaluated in an in vivo rodent model of experimental pre-eclampsia (EPE) induced by TNF-α and in an in vitro model of human first-trimester trophoblast invasion. Pregnant C57/BL6 mice were treated with recombinant mouse placental growth factor-2 (rmPlGF-2) 100 μg/kg/day IP from gestational day (gd) 10. Animals had EPE induced by continuous TNF-α infusion on gd 13 and were subject to either continuous blood pressure monitoring by radiotelemetry throughout pregnancy or live placenta T

Identifiants

pubmed: 31452230
doi: 10.1111/1440-1681.13169
doi:

Substances chimiques

Pgf protein, mouse 0
Tumor Necrosis Factor-alpha 0
Placenta Growth Factor 144589-93-5

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

49-59

Informations de copyright

© 2019 John Wiley & Sons Australia, Ltd.

Références

Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350(7):672-683.
Powers RW, Jeyabalan A, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, et al. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies. PLoS ONE. 2010;5(10):e13263.
Poon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH. Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn. 2008;28(12):1110-1115.
Sunderland N, Hennessy A, Makris A. Animal models of pre-eclampsia. Am J Reprod Immunol. 2011;65(6):533-541.
Granger JPBW, Alexander BT, Cockrell KL, Whitworth NS. Long-term elevation of plasma TNF-alpha increases arterial pressure and reduces kidney function in pregnant rats. Hypertension. 1999;34(2):337.
Murphy SR, LaMarca BB, Parrish M, Cockrell K, Granger JP. Control of soluble fms-like tyrosine-1 (sFlt-1) production response to placental ischemia/hypoxia: role of tumor necrosis factor-alpha. Am J Physiol Regul Integr Comp Physiol. 2013;304(2):R130-R135.
Bobek G, Surmon L, Mirabito KM, Makris A, Hennessy A. Placental regulation of inflammation and hypoxia after TNF-alpha infusion in mice. Am J Reprod Immunol. 2015;74(5):407-418.
Bobek G, Stait-Gardner T, Surmon L, Makris A, Lind JM, Price WS, et al. Magnetic resonance imaging detects placental hypoxia and acidosis in mouse models of perturbed pregnancies. PLoS ONE. 2013;8(3):e59971.
Spradley FT, Tan AY, Joo WS, Daniels G, Kussie P, Karumanchi SA, et al. Placental growth factor administration abolishes placental ischemia-induced hypertension. Hypertension. 2016;67(4):740-747.
Zhu M, Ren Z, Possomato-Vieira JS, Khalil RA. Restoring placental growth factor-soluble fms-like tyrosine kinase-1 balance reverses vascular hyper-reactivity and hypertension in pregnancy. Am J Physiol Regul Integr Comp Physiol. 2016;311(3):R505-R521.
Makris A, Yeung KR, Lim SM, Sunderland N, Heffernan S, Thompson JF, et al. Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in nonhuman primates. Hypertension. 2016;67(6):1263-1272.
Suzuki H, Ohkuchi A, Matsubara S, Takei Y, Murakami M, Shibuya M, et al. Effect of recombinant placental growth factor 2 on hypertension induced by full-length mouse soluble fms-like tyrosine kinase 1 adenoviral vector in pregnant mice. Hypertension. 2009;54(5):1129-1135.
Sunderland NS, Thomson SE, Heffernan SJ, Lim S, Thompson J, Ogle R, et al. Tumor necrosis factor alpha induces a model of preeclampsia in pregnant baboons (Papio hamadryas). Cytokine. 2011;56(2):192-199.
Mu J, Slevin JC, Qu D, McCormick S, Adamson SL. In vivo quantification of embryonic and placental growth during gestation in mice using micro-ultrasound. Reprod Biol Endocrinol. 2008;6:34.
Kang MC, Park SJ, Kim HJ, Lee J, Yu DH, Bae KB, et al. Gestational loss and growth restriction by angiogenic defects in placental growth factor transgenic mice. Arterioscler Thromb Vasc Biol. 2014;34(10):2276-2282.
Koga K, Mor G. Toll-like receptors at the maternal-fetal interface in normal pregnancy and pregnancy disorders. Am J Reprod Immunol. 2010;63(6):587-600.
Chatterjee P, Chiasson VL, Kopriva SE, Young KJ, Chatterjee V, Jones KA, et al. Interleukin 10 deficiency exacerbates toll-like receptor 3-induced preeclampsia-like symptoms in mice. Hypertension. 2011;58(3):489-496.
Chatterjee P, Weaver LE, Doersch KM, Kopriva SE, Chiasson VL, Allen SJ, et al. Placental Toll-like receptor 3 and Toll-like receptor 7/8 activation contributes to preeclampsia in humans and mice. PLoS ONE. 2012;7(7):e41884.
Helske S, Vuorela P, Carpen O, Hornig C, Weich H, Halmesmaki E. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod. 2001;7(2):205-210.
De Falco S. The discovery of placenta growth factor and its biological activity. Exp Mol Med. 2012;44(1):1-9.
Aasa KL, Zavan B, Luna RL, Wong PG, Ventura NM, Tse MY, et al. Placental growth factor influences maternal cardiovascular adaptation to pregnancy in mice. Biol Reprod. 2015;92(2):44.
Parchem JG, Kanasaki K, Kanasaki M, Sugimoto H, Xie L, Hamano Y, et al. Loss of placental growth factor ameliorates maternal hypertension and preeclampsia in mice. J Clin Invest. 2018;128(11):5008-5017.
National Health and Medical Research Council. Guidelines to Promote the Wellbeing of Animals Used for Scientific Purposes. Canberra, Australia: Australian Government; 2008.
Burke SD. Radiotelemetry in mouse pregnancy. In: Croy A, Yamada AT, DeMayo FJ, Adamson SL, eds. The Guide To Investigation Of Mouse Pregnancy, 1st edn. Cambridge, MA: Academic Press; 2014:649-659.
Surmon L, Bobek G, Chiu CL, Young S, Makris A, Lind JM, et al. The expression of placental soluble fms-like tyrosine kinase 1 in mouse placenta varies significantly across different litters from normal pregnant mice. Hypertens Pregnancy. 2014;33(3):371-374.
Chiu CL, Morgan CT, Lupton SJ, Lind JM. Parent of origin influences the cardiac expression of vascular endothelial growth factor (Vegfa). BMC Med Genet. 2013;14:43.
Huckle WR, Roche RI. Post-transcriptional control of expression of sFlt-1, an endogenous inhibitor of vascular endothelial growth factor. J Cell Biochem. 2004;93(1):120-132.
Xu B, Charlton F, Makris A, Hennessy A. Antihypertensive drugs methyldopa, labetalol, hydralazine, and clonidine improve trophoblast interaction with endothelial cellular networks in vitro. J Hypertens. 2014;32(5):1075-1083; discussion 83
Xu B, Shanmugalingam R, Chau K, Pears S, Hennessy A, Makris A. The effect of acetyl salicylic acid (Aspirin) on trophoblast-endothelial interaction in vitro. J Reprod Immunol. 2017;124:54-61.
Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene. 2005;24:2647.
Charlton F, Bobek G, Stait-Gardner T, Price WS, Mirabito Colafella KM, Xu B, et al. The protective effect of apolipoprotein in models of trophoblast invasion and preeclampsia. Am J Physiol Regul Integr Comp Physiol. 2017;312(1):R40-r8.
Xu B, Nakhla S, Makris A, Hennessy A. TNF-alpha inhibits trophoblast integration into endothelial cellular networks. Placenta. 2011;32(3):241-246.

Auteurs

Katrina Chau (K)

Sydney Medical School, University of Sydney, Camperdown, New South Wales, Australia.
Vascular Immunology Group, Heart Research Institute, University of Sydney, Newtown, New South Wales, Australia.
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.

Gabriele Bobek (G)

School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.

Bei Xu (B)

Vascular Immunology Group, Heart Research Institute, University of Sydney, Newtown, New South Wales, Australia.

Timothy Stait-Gardner (T)

Nanoscale Organisation and Dynamics Group, Western Sydney University, Campbelltown, New South Wales, Australia.

William Price (W)

Nanoscale Organisation and Dynamics Group, Western Sydney University, Campbelltown, New South Wales, Australia.

Annemarie Hennessy (A)

Sydney Medical School, University of Sydney, Camperdown, New South Wales, Australia.
Vascular Immunology Group, Heart Research Institute, University of Sydney, Newtown, New South Wales, Australia.
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.

Angela Makris (A)

Vascular Immunology Group, Heart Research Institute, University of Sydney, Newtown, New South Wales, Australia.
School of Medicine, Western Sydney University, Campbelltown, New South Wales, Australia.
Renal Department, Liverpool Hospital, Liverpool, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH